MedPath

Tagged News

Axle Health Raises $10M Series A to Scale AI-Powered Home Healthcare Platform

AI
  • Axle Health secured $10 million in Series A funding led by F-Prime to expand its AI-powered home healthcare logistics platform.
  • The company reported 900% growth in fiscal year 2024 and demonstrated up to 30% improvement in clinician productivity through its technology.
  • The platform integrates with existing EMR systems to optimize scheduling, routing, and patient engagement for home-based care delivery.
  • Funding will accelerate development of generative AI solutions and support team expansion as demand for home healthcare continues to surge.

Global Rheumatoid Arthritis Incidence Rises 13.2% Over Three Decades Despite Declining Mortality

AI
  • Global rheumatoid arthritis incidence increased 13.2% from 1990 to 2021, affecting 17.9 million people worldwide by 2021, with significant regional disparities and a shift toward younger age groups.
  • Despite rising incidence, RA-related mortality dropped by 32.7% over the study period, from 0.09 to 0.06 per 100,000 people, attributed to improved diagnostic capabilities and treatment advances.
  • Women face disproportionately higher disease burden than men, with mortality rates of 0.08 versus 0.04 per 100,000 people and significantly higher disability-adjusted life years.
  • AI-driven forecasting models predict continued global RA burden growth through 2040, particularly in low- and middle-income countries, highlighting urgent need for targeted public health interventions.

MSKai Spine Imaging Software Receives FDA 510(k) Clearance for Lumbar MRI Analysis

AIAIAI
  • MSKai, an AI-powered spine imaging software platform, has received FDA 510(k) clearance for clinical use in lumbar spine MRI analysis by physicians and radiologists.
  • The software enables automated anatomy segmentation, labeling, and measurement of T2-weighted lumbar spine MRIs, delivering quantitative and qualitative results within seconds.
  • MSKai functions as a decision-support tool rather than a diagnostic device, supporting clinical workflow efficiency while maintaining physician oversight and clinical judgment.
  • The clearance positions MSKai to facilitate pre-surgical authorizations and post-intervention treatment monitoring in spine care.

Caris Life Sciences Files for $300 Million IPO to Advance AI-Powered Precision Oncology Platform

Precision MedicineAIOncology
  • Caris Life Sciences has filed for an initial public offering aiming to raise up to $300 million, with plans to list on Nasdaq under the ticker symbol "CAI".
  • The company has developed an AI-powered precision medicine platform for oncology, built on a massive dataset of over 6.5 million tests from 849,000 cases, generating measurements of more than 38 billion molecular markers.
  • Caris' commercial portfolio includes MI Profile, a tissue-based molecular profiling solution, and Caris Assure, a blood-based profiling solution launched in Q1 2024 for therapy selection.

Insilico Medicine Develops AI-Designed ENPP1 Inhibitor ISM5939 for Cancer Immunotherapy

AIDrug Discovery
  • Insilico Medicine used generative AI platforms PandaOmics and Chemistry42 to discover and design ISM5939, a highly selective oral ENPP1 inhibitor that modulates the STING pathway for cancer immunotherapy.
  • ISM5939 demonstrated superior potency with IC50 values of 0.63 nM against cGAMP degradation and showed synergistic effects when combined with anti-PD-1 therapy and chemotherapy in preclinical studies.
  • The compound exhibits a wider therapeutic index compared to direct STING agonists, avoiding systemic cytokine release and T-cell apoptosis while effectively enhancing antitumor immunity in multiple solid tumor types.

Novartis Invests in Aging Research: A $550 Million Bet on the Future of Drug Development

AI
• Novartis has partnered with BioAge Labs in a deal worth up to $550 million, gaining access to one of the world's largest human longevity datasets to develop treatments for age-related diseases.
• The pharmaceutical giant established its Diseases of Aging and Regenerative Medicine (DARe) research group in 2023, focusing on understanding biological drivers of aging to potentially treat multiple age-related conditions simultaneously.
• With the global population of people over 60 expected to double to 2.1 billion by 2050, the market for geriatric medicines is projected to reach $222.5 billion by 2030, making aging research increasingly lucrative.

AI Transforms Real-World Data into Regulatory-Grade Evidence for Ophthalmology Research

AI
  • Regulatory agencies like FDA and EMA are increasingly incorporating real-world data into clinical research and regulatory decision-making, recognizing its potential to enhance drug development and improve patient outcomes.
  • AI technologies are playing a crucial role in transforming unstructured ophthalmology data from sources like electronic health records into standardized, regulatory-grade evidence that meets stringent quality requirements.
  • Verana Health's VeraQ® population health data engine is converting raw data from the American Academy of Ophthalmology IRIS® Registry into research-ready datasets that can support regulatory decisions for conditions like cataracts and neovascular age-related macular degeneration.

MindHYVE.ai Partners with Islamabad Diagnostic Centre to Deploy AGI-Powered Diagnostic Intelligence Across Pakistan

AI
  • MindHYVE.ai, a U.S.-based artificial general intelligence company, has signed a memorandum of understanding with Islamabad Diagnostic Centre to deploy AGI-powered diagnostic agents across Pakistan's healthcare system.
  • The collaboration will introduce Chiron and Ava-AutoNarrator, two proprietary AGI agents designed to enhance decision precision, speed, and reproducibility in radiology and laboratory services.
  • The three-phase rollout strategy begins with pilot deployment at flagship centers in Islamabad and Lahore, followed by expansion across 5-7 IDC locations, and ultimately scaling to IDC's 130+ branches nationwide.
  • All systems will operate under MindHYVE.ai's Ethical AGI Protocol, incorporating human-in-the-loop validation, encrypted patient data pathways, and regulatory compliance with DRAP and PNAC oversight.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.